Neuberger Berman Group
OCUL icon

Neuberger Berman Group’s Ocular Therapeutix OCUL Stock Holding History

Neuberger Berman Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.8K Buy
+10,066
New +$91.2K ﹤0.01% 2248
2022
Q4 		– Sell
-51,400
Closed -$213K – 1851
2022
Q3 		$213K Sell
51,400
-150
-0.3% -$756 ﹤0.01% 1710
2022
Q2 		$207K Sell
51,550
-8,960
-15% -$33.8K ﹤0.01% 1745
2022
Q1 		$300K Sell
60,510
-33
-0.1% -$183 ﹤0.01% 1702
2021
Q4 		$422K Buy
60,543
+4
+0% +$31 ﹤0.01% 1601
2021
Q3 		$605K Sell
60,539
-650
-1% -$7.3K ﹤0.01% 1430
2021
Q2 		$868K Sell
61,189
-350
-0.6% -$5.32K ﹤0.01% 1358
2021
Q1 		$1.01M Sell
61,539
-2,051
-3% -$39.5K ﹤0.01% 1311
2020
Q4 		$1.32M Buy
63,590
+100
+0.2% +$1.49K ﹤0.01% 1189
2020
Q3 		$483K Buy
63,490
+30
+0% +$249 ﹤0.01% 1357
2020
Q2 		$529K Buy
63,460
+220
+0.3% +$1.46K ﹤0.01% 1271
2020
Q1 		$313K Hold
63,240
– – ﹤0.01% 1332
2019
Q4 		$250K Sell
63,240
-4,000
-6% -$13.9K ﹤0.01% 1421
2019
Q3 		$204K Hold
67,240
– – ﹤0.01% 1473
2019
Q2 		$296K Buy
67,240
+26,600
+65% +$98.5K ﹤0.01% 1400
2019
Q1 		$161K Sell
40,640
-900
-2% -$3.62K ﹤0.01% 1474
2018
Q4 		$165K Hold
41,540
– – ﹤0.01% 1509
2018
Q3 		$286K Buy
41,540
+2,375
+6% +$14.9K ﹤0.01% 1446
2018
Q2 		$264K Hold
39,165
– – ﹤0.01% 1567
2018
Q1 		$255K Buy
39,165
+5,300
+16% +$29.8K ﹤0.01% 1535
2017
Q4 		$151K Sell
33,865
-4,800
-12% -$24.5K ﹤0.01% 1709
2017
Q3 		$239K Buy
38,665
+8,765
+29% +$56.4K ﹤0.01% 1468
2017
Q2 		$277K Buy
+29,900
New +$289K ﹤0.01% 1433

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neuberger Berman Group's OCUL Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 10,066 shares worth $98.8K. The stake represents ﹤0.01% of the portfolio and ranks #2248 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in OCUL as recently as Q3 2022.

Neuberger Berman Group first reported a position in OCUL in Q2 2017 and has held it in 23 quarters since. The position peaked at $1.32M in Q4 2020. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Neuberger Berman Group held 10,066 shares of Ocular Therapeutix worth $98.8K as of Q2 2026.
  • Ocular Therapeutix was a new Neuberger Berman Group position in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2248 holding.
  • Neuberger Berman Group first reported a position in Ocular Therapeutix in Q2 2017 and has held it in 23 quarters since.
  • Neuberger Berman Group's Ocular Therapeutix position peaked at $1.32M in Q4 2020.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.